Source comparison
Melanotan-2 for Women: Peptide Comparison
Different melanocortin pathway modulators demonstrate distinct receptor selectivity profiles and female-specific response patterns. Melanotan-2 MC1R, MC3R, MC4R, MC5R (non-selective) Higher nausea rates; documented sexual arousal effects; mole darkening univer
This comparison does not assign a generated winner or score.
- Different melanocortin pathway modulators demonstrate distinct receptor selectivity profiles and female-specific response patterns.
- Melanotan-2
- MC1R, MC3R, MC4R, MC5R (non-selective)
- Higher nausea rates; documented sexual arousal effects; mole darkening universal
- 1,000× natural α-MSH potency
- Significant (MC4R-mediated, 18–22% caloric reduction)
- Most researched melanocortin analog; non-selective binding creates broader effect profile and adverse event range
- Melanotan-1
- MC1R-selective
- Lower nausea incidence; minimal sexual or appetite effects; similar mole darkening
- 500× natural α-MSH potency
- Minimal to none
- Safer adverse event profile due to MC4R-sparing action; less research data in female cohorts
- α-MSH (natural)
- MC1R, MC3R, MC4R, MC5R (physiologic)
- Requires 200–500× higher doses; extremely short half-life (minutes)
- Baseline comparator
- Minimal at physiologic levels
- Impractical for research due to rapid enzymatic degradation; used as reference standard only
- Bremelanotide (PT-141)
- MC3R, MC4R-selective
- FDA-approved for female hypoactive sexual desire disorder; no tanning effect
- None (MC1R-sparing)
- Moderate (MC4R activation)
- Repurposed Melanotan-2 derivative; selectivity achieved through structural modification
- The comparison demonstrates why peptide structure matters. Melanotan 1 and Melanotan-2 differ by only two amino acids, yet their receptor selectivity profiles create entirely different experimental utility and safety considerations.